Critical Contrast: Nemaura Medical (NASDAQ:NMRD) Versus ICU Medical (NASDAQ:ICUI)
Critical Contrast: Nemaura Medical (NASDAQ:NMRD) Versus ICU Medical (NASDAQ:ICUI)
Nemaura Medical (NASDAQ:NMRD – Get Rating) and ICU Medical (NASDAQ:ICUI – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
納斯達克：Nemaura Medical(代碼：NMRD-GET Rating)和ICU Medical(納斯達克：ICUI-GET Rating)都是醫療公司，但哪一家是優勢投資？我們將根據這兩家公司的風險、收益、分析師建議、股息、估值、盈利能力和機構持股的強弱對它們進行比較。
Earnings and Valuation
收益和估值
This table compares Nemaura Medical and ICU Medical's gross revenue, earnings per share and valuation.
此表比較了Nemaura Medical和ICU Medical的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nemaura Medical | $500,000.00 | 100.26 | -$13.89 million | ($0.62) | -3.35 |
| ICU Medical | $1.32 billion | 2.73 | $103.14 million | $0.42 | 358.58 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Nemaura醫療 | $500,000.00 | 100.26 | -1,389萬元 | ($0.62) | -3.35 |
| ICU醫療 | 13.2億美元 | 2.73 | 1.0314億美元 | $0.42 | 358.58 |
ICU Medical has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.
ICU醫療的收入和收益高於Nemaura醫療。Nemaura Medical的市盈率低於ICU Medical，這表明它目前是兩隻股票中更負擔得起的一隻。
Insider & Institutional Ownership
內部人與機構所有權
Risk & Volatility
風險與波動性
Nemaura Medical has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Nemaura Medical的貝塔係數為-0.01，這意味着其股價的波動性比標準普爾500指數低101%。相比之下，ICU Medical的貝塔係數為0.57，這意味着其股價的波動性比標準普爾500指數低43%。
Analyst Recommendations
分析師建議
This is a breakdown of current recommendations for Nemaura Medical and ICU Medical, as reported by MarketBeat.
這是MarketBeat報道的Nemaura Medical和ICU Medical的當前建議的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nemaura Medical | 0 | 0 | 1 | 0 | 3.00 |
| ICU Medical | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Nemaura醫療 | 0 | 0 | 1 | 0 | 3.00 |
| ICU醫療 | 0 | 0 | 2 | 0 | 3.00 |
Nemaura Medical presently has a consensus price target of $8.00, indicating a potential upside of 284.62%. ICU Medical has a consensus price target of $207.50, indicating a potential upside of 37.78%. Given Nemaura Medical's higher probable upside, analysts plainly believe Nemaura Medical is more favorable than ICU Medical.
Nemaura Medical目前的共識目標價為8.00美元，表明潛在上漲284.62%。ICU Medical的共識目標價為207.50美元，表明潛在漲幅為37.78%。鑑於Nemaura Medical更有可能上行，分析師顯然認為Nemaura Medical比ICU Medical更有利。
Profitability
盈利能力
This table compares Nemaura Medical and ICU Medical's net margins, return on equity and return on assets.
此表比較了Nemaura Medical和ICU Medical的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Nemaura Medical | N/A | -3,060.48% | -57.81% |
| ICU Medical | 0.31% | 6.97% | 3.99% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Nemaura醫療 | 不適用 | -3,060.48% | -57.81% |
| ICU醫療 | 0.31% | 6.97% | 3.99% |
Summary
摘要
ICU Medical beats Nemaura Medical on 10 of the 13 factors compared between the two stocks.
ICU Medical在兩隻股票比較的13個因素中有10個擊敗了Nemaura Medical。
About Nemaura Medical
Nemaura醫療公司簡介
(Get Rating)
(獲取評級)
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc.是一家醫療技術公司，負責發現、開發和商業化診斷醫療設備。它提供SugarBEAT，一種供I型和II型糖尿病患者使用的非侵入性連續血糖監測設備，以及篩查糖尿病前期患者。該公司還提供ProBEAT，一種健康指導筆記，提供提示並教育用户有關影響血糖曲線的因素，以及開展糖尿病預防和逆轉計劃。Nemaura Medical Inc.成立於2009年，總部設在紐約。
About ICU Medical
關於ICU醫療
(Get Rating)
(獲取評級)
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
ICU醫療公司及其子公司在全球範圍內開發、製造和銷售用於輸液治療和危重護理應用的醫療設備。該公司的輸液治療產品包括MicroClave、MicroClave Clear和NanoClave品牌的無針產品；中子導管通暢設備；SwabCap和SwabTip消毒帽；Tego血液透析連接器；ClearGuard HD，血液透析導管的抗菌屏障帽；ChemoClave和ChemoLock封閉式系統傳輸設備，以及用於製備危險藥物的Diana危險藥物複合系統。它還提供靜脈治療和稀釋劑，如氯化鈉、葡萄糖、平衡電解質溶液、乳酸林格氏症、林格氏症、甘露醇、氯化鈉/葡萄糖和無菌水；灌溉包括氯化鈉和無菌水灌溉、生理溶液、林格氏灌溉、醋酸灌溉、甘氨酸灌溉、山梨醇-甘露醇灌溉、彈性容器和灌裝瓶選項。該公司提供Plum 360和LifeCare PCA品牌的輸液泵；IV中介安全軟件，包括ICU Medical MedNet，這是一個企業級藥物管理平臺，將智能泵連接到醫院的電子健康記錄、資產跟蹤系統和警報通知平臺；以及相關專業服務。該公司還提供重症監護產品，如Cogent二合一和心臟Flo血流動力學監測系統；TDQ和OptiQ心輸出量監測導管；TriOx靜脈血氧儀導管；TRANSPAC血壓傳感器；以及SafeSet封閉式血液採樣和保存系統。該公司將其產品銷售給急性護理醫院、批發商、門診診所和備用場所設施，包括門診診所、家庭保健提供者和長期護理設施。ICU醫療, 公司成立於1984年，總部設在加利福尼亞州聖克萊門特。
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nemaura醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nemaura Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。